Want to see BWAY full AI Analyst Report?
BWAY Stock Chart & Stats
$14.43
-$0.09(-0.56%)
At close: 4:00 PM EDT
$14.43
-$0.09(-0.56%)
Day’s Range― - ―
52-Week Range$7.14 - $17.40
Previous CloseN/A
Volume84.09K
Average Volume (3M)108.88K
Market Cap
$478.59M
Enterprise Value$567.18M
Total Cash (Recent Filing)$62.36M
Total Debt (Recent Filing)$7.13M
Price to Earnings (P/E)49.1
Beta1.44
Next Earnings
Nov 18, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding40,252,990
10 Day Avg. Volume113,919
30 Day Avg. Volume108,881
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.48
Price to Sales (P/S)3.47
P/FCF Ratio11.06
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue9.30
Enterprise Value/Gross Profit12.35
Enterprise Value/Ebitda46.56
Forecast
1Y Price Target
$19.50Price Target Upside35.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.32
Revenue Forecast (FY)$69.16M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability GrowthStrong revenue growth alongside sharply higher EBITDA and a 20% margin indicates operating leverage as demand scales. If sustained, this combination can improve internally funded expansion, reinforce commercial execution, and support durable earnings growth over the next several quarters.
Installed-base And Contract VisibilityA growing installed base supports recurring helmet, service, and usage-related revenue as more providers treat patients. Rising remaining performance obligations also improve forward visibility, making future revenue less dependent on entirely new site wins each quarter.
Improving Reimbursement AccessBroader insurer coverage reduces a key barrier to provider and patient adoption of SWIFT. Expanded reimbursement pathways can increase utilization across existing sites, make new installations easier to justify, and strengthen BrainsWay's position in interventional psychiatry.
Bears Say
Volatile Cash ConversionPositive cash generation is encouraging, but the sharp decline in trailing free cash flow shows that reported earnings have not converted consistently into cash. Persistent volatility could constrain self-funded investment and make results more sensitive to working-capital movements.
Rising Operating ExpensesHigher R&D and G&A spending may support clinical development and commercial growth, but it also creates execution pressure on margins. If expense growth continues faster than revenue or productive launches, profitability improvements could prove less durable than recent results suggest.
Payer And Reimbursement DependenceBrainsWay's growth depends not only on clinical performance but also on insurers approving and funding treatment. Local policy variation can slow provider adoption, produce uneven utilization across markets, and make the timing of commercial expansion less predictable.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $7.13 and its highest was $17.40 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $478.59M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Nov 18, 2026 which is in 26 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Aug 12, 2026. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.073 by -$0.003.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Undervalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.09.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,252,990 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.07 in its last earnings report, missing expectations of $0.073. Following the earnings report the stock price went up 10.814%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.50 (35.14% Upside)
$19.50 (35.14% Upside)
Blogger Sentiment
Neutral
BWAY Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 51.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.58%
12-Months-Change
Fundamentals
Return on Equity
12.69%
Trailing 12-Months
Asset Growth
9.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Brainsway Ltd
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company delivered strong top-line growth (35% YoY), significant margin and profitability expansion (operating income +300% YoY; adjusted EBITDA +141% YoY), increased installed base and RPOs, raised full-year guidance, and presented supportive clinical/reimbursement data (SWIFT durability and PTSD+MDD real-world results). Noted risks relate to increased R&D/G&A spending, dependence on payer adoption and local reimbursement variability, early-stage nature and timing of contributions from minority investments (including Neurolief), and the timing of backlog revenue recognition. Overall, the positives—robust growth, margin expansion, strengthened cash position, and clinical momentum—significantly outweigh the operational and timing risks discussed.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$19.50
▲(35.14% Upside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
0.16% Insiders
1.18% Mutual Funds
1.16% Other Institutional Investors
96.80% Public Companies and
Individual Investors